Abstract
The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kang HN, Thorpe R, Knezevic I. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020;65:1–9.
Jois R, Mukherjee S, Rajeswari S, et al. Similar biologics in India: A story of access or potential for compromise? Indian J Med Res. 2020;152:456.
Grisar J. Biologicals and how they revolutionized rheumatology. Wien Med Wochenschr. 2015;165:1–2.
Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Sem Arthritis Rheumat. 2017;46:584–93.
Murray GM, Sen ES, Ramanan AV. Advancing the treatment of juvenile idiopathic arthritis. Lancet Rheumatol. 2021;3: e294–305.
Sarzi-Puttini P, Varisco V, Ditto MC, et al. Psoriatic arthritis registries. J Rheu Sup. 2015;93:30–2.
Mak JW, Sung JJ. The use of biologics and biosimilar in asian patients with IBD: Are we ready?: The use of biologics and biosimilar in Asian patients with IBD: Are we ready?. J Gastro Hepatology. 2019;34:1269–70.
Henderson LA, Canna SW, Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV 2 and hyperinflammation in pediatric COVID 19: version 1. Arthritis Rheumatol. 2020;72:1791–805.
Clarke SLN, Ramanan AV. Tofacitinib in juvenile idiopathic arthritis. Lancet. 2021;398:1943–45.
Gooderham M, Papp K. Clinical trial and registry data. Curr Probl Dermatol. 2018;53:15–27.
Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66: 2580–89.
Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo. 2008;60:290–5.
Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: Data from the Spanish registry BIOBADASER 2.0. Rheumatol. 2011;50:85–92.
Saini I, Dawman L, Gupta N, Kabra SK. Biologicals in juvenile idiopathic arthritis. Indian Pediatr. 2016;53:260–1.
Ai JW, Zhang S, Ruan QL, et al. The Risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: A meta analysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015; 42:2229–37.
Verma M, Pandey NN, Bagri NK, et al. Multiple tubercular aortic aneurysms in a case of chronic noninfectious osteomyelitis. Indian J Pediatr. 2022;89:812–13.
Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis. 2017;20:1313–25.
Horneff G, Klein A, Oommen PT, et al. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol. 2016;34: 1113–20.
Zhao Y, Sullivan E, Son MB, Beukelman T. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA. Ann Rheumatic Dis. 2022;81:662–65.
Giancane G, Swart JF, Castagnola E, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71.
El Zorkany B, AlWahshi HA, Hammoudeh M, et al. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: Could the EULAR recommendations be the start of a solution? Clin Rheumatol. 2013;32:151–9.
Klein A, Klotsche J, Hügle B, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology. 2020;59:2287–98.
Becker I, Horneff G. Risk of Serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2017;69:552–60.
Armaroli G, Klein A, Ganser G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther. 2020;22:258.
Giancane G, Swart JF, Castagnola E, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71.
Kearsley-Fleet L, Klotsche J, van Straalen JW, et al. Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: A collaborative analysis of 3 JIA registries. Rheumatology (Oxford). 2021;61:2524–34.
Funding
None
Author information
Authors and Affiliations
Contributions
NKB, AVR: concept and design; NKB: literature review and compiled the initial draft; SK, AVR: reviewed the draft for intellectual inputs. All authors contributed and approved the final version of the manuscript.
Corresponding author
Additional information
Competing interests
None stated.
Rights and permissions
About this article
Cite this article
Bagri, N.K., Kumar, S. & Ramanan, A.V. Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward. Indian Pediatr 59, 913–915 (2022). https://doi.org/10.1007/s13312-022-2661-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-022-2661-8